zirconium has been researched along with dasatinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aragon-Sanabria, V; Bradbury, MS; Brennan, CW; Carlin, S; Chen, F; Chen, PM; Gonen, M; Huse, J; Juthani, R; Longo, VA; Ma, K; Madajewski, B; Overholtzer, M; Rudin, CM; Turker, MZ; Wiesner, U; Yoo, B; Zanzonico, P; Zhang, L | 1 |
| Boerner, JL; Kim, S; McKnight, BN; Viola, NT | 1 |
2 other study(ies) available for zirconium and dasatinib
| Article | Year |
|---|---|
Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dasatinib; Disease Models, Animal; Drug Delivery Systems; Glioblastoma; Iodine Radioisotopes; Mice; Nanoparticles; Neoplasm Grading; Oligopeptides; Positron-Emission Tomography; Protein Kinase Inhibitors; Radioisotopes; Silicon Dioxide; Zirconium | 2020 |
Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
Topics: Animals; Antineoplastic Agents, Immunological; Cell Line, Tumor; Cell Proliferation; Cetuximab; Dasatinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Mice; Mice, Nude; Positron-Emission Tomography; Protein Kinase Inhibitors; Radioisotopes; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays; Zirconium | 2020 |